查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
HIV治疗药的全球市场:市场规模 - 各药物类别，各投药法，各流通管道，各地区展望，竞争策略，各市场区隔预测(～2032年)
市场调查报告书
商品编码
1174975

HIV治疗药的全球市场:市场规模 - 各药物类别，各投药法，各流通管道，各地区展望，竞争策略，各市场区隔预测(～2032年)

HIV Drugs Market Size- By Drug Class, By Administration, By Distribution Channel- Regional Outlook, Competitive Strategies and Segment Forecasts to 2032
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 232 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

全球HIV治疗药的市场规模，预计至2032年达到4,974万美元，预计以4.05％的年复合成长率成长。

HIV的感染率和诊断数增加，是牵引全球市场的成长的重要要素之一。以提高原因、症状、治疗方法相关国民的知识为目的的政府活动增加，也带给市场影响。

本报告提供全球HIV治疗药市场相关调查，市场动态，市场变数与展望，各药物类别、投药法、流通管道、地区的市场分析，企业简介等相关资讯。

目录

第1章 简介

  • 调查范围
  • 市场区隔分析

第2章 调查手法

  • 调查资料来源
  • 市场规模的估计
  • 资料的三角测量

第3章 摘要整理

第4章 市场动态

  • 促进因素，阻碍因素，机会，课题的分析
    • 促进因素
    • 阻碍因素
    • 机会
    • 课题
  • 全球HIV治疗药市场上COVID-19的影响

第5章 市场变数与展望

  • SWOT分析
    • 优势
    • 弱点
    • 机会
    • 威胁
  • PESTEL分析
    • 政治形势
    • 经济形势
    • 社会形势
    • 技术形势
    • 环境形势
    • 法律上的形势
  • 波特的五力分析
    • 供给企业谈判力
    • 买方议价能力
    • 替代品的威胁
    • 新加入厂商的威胁
    • 竞争企业间的敌对关係
  • 热图分析

第6章 全球HIV治疗药市场:各药物类别(2019年～2032年(100万美元))

  • 趋化素受体抑制剂
  • 进入抑制剂 - CCR5共受体拮抗剂
  • 融合抑制剂
  • 整合抑制剂，HIV整合酶链转移抑制剂
  • 多级组合产品，蛋白酶抑制剂
  • 非核苷系逆转录酶抑制剂(NNRT)
  • 核苷系逆转录酶抑制剂(NRT)

第7章 全球HIV治疗药市场:各投药法(2019年～2032年(100万美元))

  • 口服
  • 非口服

第8章 全球HIV治疗药市场:各流通管道(2019年～2032年(100万美元))

  • 医院药局
  • 线上药局
  • 零售药局
  • 其他

第9章 全球HIV治疗药市场:各地区(2019年～2032年(100万美元))

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他的欧洲
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 其他的亚太地区
  • 南美
    • 巴西
    • 阿根廷
    • 其他的南美
  • 中东、非洲
    • 沙乌地阿拉伯王国
    • 阿拉伯联合大公国
    • 其他的中东、非洲

第10章 企业简介

  • Abbvie Inc.
    • 企业概要
    • 财务展望
    • 产品概要
    • 最近的开发
  • Aelix Therapeutics
  • AIM ImmunoTech
  • BioNTech
  • Biosantech
  • Boehringer Ingelheim International GmbH
  • Bristrol-Myers Squibb Company
  • CytoDyn
  • Dewpoint Therapeutics
  • Gilead Sciences
  • GlaxoSmithKline
  • ImmunityBio
  • Janssen Pharmaceuticals
  • Japan Tobacco
  • Merck
  • Mylan
  • Roche
  • Shionogi
  • Starpharma
  • TaiMed Biologics
  • Theratechnologies
  • ViiV Heathcare
简介目录
Product Code: PHAR2213

Global HIV Drugs Market Overview:

According to SPER Market Research, the Global HIV Drugs Market is estimated to reach USD 49.74 million by 2032 with a CAGR of 4.05%.

The chronic and potentially fatal human immunodeficiency virus (HIV) can be spread to humans to another through sexual contact and blood-to-blood contact. It is a virus that targets CD-4 cells, which are immunological cells, rendering the body more vulnerable to infections and other disorders. The demand for HIV medications has benefited from the increasing incidence of HIV illness throughout time. HIV medications assist in inhibiting HIV replication, hence lowering the risk of transmission. The increase in HIV prevalence and its diagnosis is one of the key reasons driving the growth of the worldwide market for HIV medications. In addition, a growth in the number of government activities aimed at raising public knowledge of causes, symptoms, and treatments has an impact on the market. The availability of generic medications, which are as effective and chemically equivalent to branded medications, is another factor influencing the demand for HIV medications.

Impact of COVID-19 on the Global HIV Drugs Market

Global healthcare goods import, and export have been hampered by the COVID-19 epidemic. Because of the disruption and volatility in the medicine supply, the pandemic has had a negative effect on the growth of this industry. Additionally, the demand for antiretroviral and antibiotic drugs has decreased internationally due to the decline in the number of new patient prescriptions in the United States, Europe, and other COVID-affected areas and nations. The majority of businesses have seen a negative effect of the epidemic on the sales of HIV/AIDS medications.

Scope of the Report:

  • Market size available for years: 2019-2032
  • Base year considered: 2021
  • Forecast period: 2022-2032
  • Segments covered: By Drug Class, By Administration, By Distribution Channel
  • Regions covered: North America, Europe, Asia Pacific, Latin America, Middle East and Africa
  • Companies Covered: Abbvie Inc., Aelix Therapeutics, AIM ImmunoTech, BioNTech, Biosantech, Boehringer Ingelheim International GmbH, Bristrol-Myers Squibb Company, CytoDyn, Dewpoint Therapeutics, Gilead Sciences, GlaxoSmithKline, ImmunityBio, Janssen Pharmaceuticals, Japan Tobacco, Merck, Mylan, Roche, Shionogi, Starpharma, TaiMed Biologics, Theratechnologies, ViiV Healthcare.

Global HIV Drugs Market Segmentation:

  • By Drug Class: Based on the Drug Class, Global HIV Drugs Market is segmented as; Chemokine Receptor Inhibitors, Entry Inhibitors - CCR5 Co-Receptor Antagonist, Fusion Inhibitors, Integrate Inhibitors, HIV Integrase Strand Transfer Inhibitors, Multi-Class Combination Products, Protease Inhibitors, Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT's), Nucleoside Reverse Transcriptase Inhibitors (NRT's).
  • By Administration: Based on the Administration, Global HIV Drugs Market is segmented as; Oral, Parenteral.
  • By Distribution Channel: Based on the Distribution Channel, Global HIV Drugs Market is segmented as; Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Others.
  • By Region: The worldwide market may be divided into three regions based on geography: North America, Europe, and the rest of the world. It is expected that North America would predominate. The rising incidence of HIV infection among Americans is to blame for this region's dominance. The demand for HIV medications is greatly increased by a large patient base. The population's awareness is another element influencing the progress of the region. Additionally, the existence of major companies that provide cutting-edge HIV medications for the treatment of HIV infection will further accelerate market expansion. Rapid increase in the number of HIV infections and the abundance of HIV medicine manufacturers in this area, Europe is anticipated to be the second-largest market throughout the projection period.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1 Research data source
    • 2.1.1 Secondary data
    • 2.1.2 Primary data
    • 2.1.3 SPER's internal database
    • 2.1.4 Premium insight from KOL's
  • 2.2 Market size estimation
    • 2.2.1 Top-down and Bottom-up approach
  • 2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1 Drivers
    • 4.1.2 Restraints
    • 4.1.3 Opportunities
    • 4.1.4 Challenges
  • 4.2. COVID-19 Impacts of the Global HIV Drugs Market

5. Market variables and outlook

  • 5.1. SWOT analysis
    • 5.1.1 Strengths
    • 5.1.2 Weaknesses
    • 5.1.3 Opportunities
    • 5.1.4 Threats
  • 5.2. PESTEL analysis
    • 5.2.1 Political landscape
    • 5.2.2 Economic landscape
    • 5.2.3 Social landscape
    • 5.2.4 Technological landscape
    • 5.2.5 Environmental landscape
    • 5.2.6 Legal landscape
  • 5.3. PORTER'S five forces analysis
    • 5.3.1 Bargaining power of suppliers
    • 5.3.2 Bargaining power of Buyers
    • 5.3.3 Threat of Substitute
    • 5.3.4 Threat of new entrant
    • 5.3.5 Competitive rivalry
  • 5.4. Heat map analysis

6. Global HIV Drugs Market, By Drug Class, 2019-2032 (USD Million)

  • 6.1. Chemokine Receptor Inhibitors
  • 6.2. Entry Inhibitors - CCR5 Co-Receptor Antagonist
  • 6.3. Fusion Inhibitors
  • 6.4. Integrate Inhibitors, HIV Integrase Strand Transfer Inhibitors
  • 6.5. Multi-Class Combination Products, Protease Inhibitors
  • 6.6. Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT's)
  • 6.7. Nucleoside Reverse Transcriptase Inhibitors (NRT's)

7. Global HIV Drugs Market, By Administration, 2019-2032 (USD Million)

  • 7.1. Oral
  • 7.2. Parenteral

8. Global HIV Drugs Market, By Distribution Channel, 2019-2032 (USD Million)

  • 8.1. Hospital Pharmacies
  • 8.2. Online Pharmacies
  • 8.3. Others
  • 8.4. Retail Pharmacies

9. Global HIV Drugs Market, By Region, 2019-2032 (USD Million)

  • 9.1 North America
    • 9.1.1 United States
    • 9.1.2 Canada
    • 9.1.3 Mexico
  • 9.2 Europe
    • 9.2.1 Germany
    • 9.2.2 United Kingdom
    • 9.2.3 France
    • 9.2.4 Italy
    • 9.2.5 Spain
    • 9.2.6 Rest of Europe
  • 9.3 Asia-Pacific
    • 9.3.1 China
    • 9.3.2 Japan
    • 9.3.3 India
    • 9.3.4 Australia
    • 9.3.5 South Korea
    • 9.3.6 Rest of Asia-Pacific
  • 9.4 South America
    • 9.4.1 Brazil
    • 9.4.2 Argentina
    • 9.4.3 Rest of South America
  • 9.5 Middle East & Africa
    • 9.5.1 Kingdom of Saudi Arabia
    • 9.5.2 United Arab Emirates
    • 9.5.3 Rest of Middle East & Africa

10. Company Profiles

  • 10.1 Abbvie Inc.
    • 10.1.1 Company details
    • 10.1.2 Financial outlook
    • 10.1.3 Product summary
    • 10.1.4 Recent developments
  • 10.2 Aelix Therapeutics
    • 10.2.1 Company details
    • 10.2.2 Financial outlook
    • 10.2.3 Product summary
    • 10.2.4 Recent developments
  • 10.3 AIM ImmunoTech
    • 10.3.1 Company details
    • 10.3.2 Financial outlook
    • 10.3.3 Product summary
    • 10.3.4 Recent developments
  • 10.4 BioNTech
    • 10.4.1 Company details
    • 10.4.2 Financial outlook
    • 10.4.3 Product summary
    • 10.4.4 Recent developments
  • 10.5 Biosantech
    • 10.5.1 Company details
    • 10.5.2 Financial outlook
    • 10.5.3 Product summary
    • 10.5.4 Recent developments
  • 10.6 Boehringer Ingelheim International GmbH
    • 10.6.1 Company details
    • 10.6.2 Financial outlook
    • 10.6.3 Product summary
    • 10.6.4 Recent developments
  • 10.7 Bristrol-Myers Squibb Company
    • 10.7.1 Company details
    • 10.7.2 Financial outlook
    • 10.7.3 Product summary
    • 10.7.4 Recent developments
  • 10.8 CytoDyn
    • 10.8.1 Company details
    • 10.8.2 Financial outlook
    • 10.8.3 Product summary
    • 10.8.4 Recent developments
  • 10.9 Dewpoint Therapeutics
    • 10.9.1 Company details
    • 10.9.2 Financial outlook
    • 10.9.3 Product summary
    • 10.9.4 Recent developments
  • 10.10 Gilead Sciences
    • 10.10.1 Company details
    • 10.10.2 Financial outlook
    • 10.10.3 Product summary
    • 10.10.4 Recent developments
  • 10.11 GlaxoSmithKline
    • 10.11.1 Company details
    • 10.11.2 Financial outlook
    • 10.11.3 Product summary
    • 10.11.4 Recent developments
  • 10.12 ImmunityBio
    • 10.12.1 Company details
    • 10.12.2 Financial outlook
    • 10.12.3 Product summary
    • 10.12.4 Recent developments
  • 10.13 Janssen Pharmaceuticals
    • 10.13.1 Company details
    • 10.13.2 Financial outlook
    • 10.13.3 Product summary
    • 10.13.4 Recent developments
  • 10.14 Japan Tobacco
    • 10.14.1 Company details
    • 10.14.2 Financial outlook
    • 10.14.3 Product summary
    • 10.14.4 Recent developments
  • 10.15 Merck
    • 10.15.1 Company details
    • 10.15.2 Financial outlook
    • 10.15.3 Product summary
    • 10.15.4 Recent developments
  • 10.16 Mylan
    • 10.16.1 Company details
    • 10.16.2 Financial outlook
    • 10.16.3 Product summary
    • 10.16.4 Recent developments
  • 10.17 Roche
    • 10.17.1 Company details
    • 10.17.2 Financial outlook
    • 10.17.3 Product summary
    • 10.17.4 Recent developments
  • 10.18 Shionogi
    • 10.18.1 Company details
    • 10.18.2 Financial outlook
    • 10.18.3 Product summary
    • 10.18.4 Recent developments
  • 10.19 Starpharma
    • 10.19.1 Company details
    • 10.19.2 Financial outlook
    • 10.19.3 Product summary
    • 10.19.4 Recent developments
  • 10.20 TaiMed Biologics
    • 10.20.1 Company details
    • 10.20.2 Financial outlook
    • 10.20.3 Product summary
    • 10.20.4 Recent developments
  • 10.21 Theratechnologies
    • 10.21.1 Company details
    • 10.21.2 Financial outlook
    • 10.21.3 Product summary
    • 10.21.4 Recent developments
  • 10.22 ViiV Heathcare
    • 10.22.1 Company details
    • 10.22.2 Financial outlook
    • 10.22.3 Product summary
    • 10.22.4 Recent developments